Hyperuricemia
Recent clinical, regulatory, research and industry developments relating to this disease.
ULTRA-T2D Study: Uric Acid Lowering Trial in Youth Onset T2D
ULTRA-T2D Study: Uric Acid Lowering Trial in Youth Onset T2D
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 4 clinical trials expected to report results, the earliest in Q1 2027.
- Q1 2027A Phase 1, Double-blinded, Placebo-controlled Study of Single Ascending Doses of NNC4004-0002 in Adults With Asymptomatic Hyperuricemia
- Q3 2027A Multicenter, Randomized, Double-blind, Active-controlled Parallel-group Phase ii Clinical Study to Compare the Efficacy and Safety of SHR4640 Tablets Combined With Febuxostat Tablets at 40 mg/Day Versus Febuxostat Tablets With Dose Escalation in Treatment of Primary Gout and Hyperuricemia Subjects With Inadequate Control on 40 mg/Day Febuxostat
- Q3 2027Effect of Dotinurad in Hyperuricemia With Hypertension: a Randomized Study With Febuxostat (DIANA-NEXT)
- Q1 2028SAVE-Care (SGLT2i As Novel Gout Care) Trial
Clinical MilestonesViewHide
- 2026-10-26A Phase 1, Double-blinded, Placebo-controlled Study of Single Ascending Doses of NNC4004-0002 in Adults With Asymptomatic HyperuricemiaResults expected Q1 2027
- 2026-08-05SAVE-Care (SGLT2i As Novel Gout Care) TrialResults expected Q1 2028
- 2026-04-07A Multicenter, Randomized, Double-blind, Active-controlled Parallel-group Phase ii Clinical Study to Compare the Efficacy and Safety of SHR4640 Tablets Combined With Febuxostat Tablets at 40 mg/Day Versus Febuxostat Tablets With Dose Escalation in Treatment of Primary Gout and Hyperuricemia Subjects With Inadequate Control on 40 mg/Day FebuxostatResults expected Q3 2027
- 2025-12-15Effect of Dotinurad in Hyperuricemia With Hypertension: a Randomized Study With Febuxostat (DIANA-NEXT)Results expected Q3 2027
- 2026-10-26ClinicalA Phase 1, Double-blinded, Placebo-controlled Study of Single Ascending Doses of NNC4004-0002 in Adults With Asymptomatic HyperuricemiaResults expected Q1 2027
- 2026-08-05ClinicalSAVE-Care (SGLT2i As Novel Gout Care) TrialResults expected Q1 2028
- 2026-05-30ClinicalComparative Study Evaluating the Outcome of Febuxostat Versus Vitamin E in Hyperuricemia Patients With Non-alcoholic Steatohepatitis Without CirrhosisPrimary completion
- 2026-04-07ClinicalA Multicenter, Randomized, Double-blind, Active-controlled Parallel-group Phase ii Clinical Study to Compare the Efficacy and Safety of SHR4640 Tablets Combined With Febuxostat Tablets at 40 mg/Day Versus Febuxostat Tablets With Dose Escalation in Treatment of Primary Gout and Hyperuricemia Subjects With Inadequate Control on 40 mg/Day FebuxostatResults expected Q3 2027
- 2025-12-31ClinicalExploratory Study on the Treatment of Gout With Potassium Citrate Sustained-release TabletsPrimary completion
- 2025-12-15ClinicalEffect of Dotinurad in Hyperuricemia With Hypertension: a Randomized Study With Febuxostat (DIANA-NEXT)Results expected Q3 2027
Clinical trials
The current development programme across all trial phases.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes8
- Gout2
- Hyperuricemia2
- Arthritis, Gouty1
- Dysbiosis1
- Gastrointestinal Microbiome1
- Prebiotics1
- Probiotics1
- Uric Acid1
Leading journals2
- Frontiers in immunology1
- World journal of gastroenterology1
Leading researchers8
- Chen X1
- Deng Y1
- Durairajan SSK1
- Fu X1
- Iyaswamy A1
- Li C1
- Li D1
- Li Y1
Affiliations (unnormalised)6
- Center for Excellence in Post-Harvest Technologies1
- Guizhou Provincial People's Hospital1
- Karpagam Academy of Higher Education1
- Ministry of Education Key Laboratory of Pharmacology of Traditional Chinese Medical Formulae1
- Nephrology Institute of Guangdong Provincial Academy of Chinese Medical Sciences (NIGH-CM)1
- School of Biomedical Sciences1
Associated genes
Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.
Disease biology
Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Reference
Authoritative identity, definition & identifiers.
Excessive URIC ACID or urate in blood as defined by its solubility in plasma at 37 degrees C; greater than 0.42mmol per liter (7.0mg/dL) in men or 0.36mmol per liter (6.0mg/dL) in women. This condition is caused by overproduction of uric acid or impaired renal clearance. Hyperuricemia can be acquired, drug-induced or genetically determined (LESCH-NYHAN SYNDROME). It is associated with HYPERTENSION and GOUT.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.